Variant · Snv
XRCC1 Q399R
CI-VAR-00003535Explore in graph →NP_006288.2:p.Gln399ArgNM_006297.2:c.1196A>GClinVar 225976 CIViC 261 rs25487
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22551904
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma1 | ||||||||
| XRCC1 Q399R | (prognostic) | Prognostic | B | Supports Better Outcome | 4 | accepted | EID672The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum. 62 patients with either Stage… (full text at CIViC) PMID 22551904 · Liao et al., 2012 · Open in CIViC | civic |
| Malignant Cervical Neoplasm1 | ||||||||
| XRCC1 Q399R | Carboplatin + CisplatinSubstitutes | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID673The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (g… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available